0
     

Report Added
Report already added
Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027

Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027

The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.Market is driven by factors such as indication of infectious diseases, growing trend in POC testing and rising technological advancements. However,an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the forecasted years.

“The reagents, kits, and consumablesaccounted for the largest market sharein theinfectious disease diagnostics market, byproduct& service, during the forecast period”

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021. Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages. This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.

“Mosquito-borne diseasessegment accounted for the highest CAGR”

Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the mosquito-borne diseasessegment accounted for the highest CAGR.

“Diagnostic Laboratoriessegment accounted for the largest market share”

Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021. This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
•By Designation: C-level - 27%, D-level - 18%, and Others - 55%
•By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lits of Companies Profiled in the Report:
•Abbott Laboratories (US)
•F. Hoffmann-La Roche Ltd. (Switzerland)
•bioMérieux SA (France)
•Thermo Fisher Scientific Inc. (US)
•Danaher Corporation (US)
•QuidelCorporation(US)
•Hologic, Inc. (US)
•PerkinElmer Inc. (US)
•Bio-Rad Laboratories, Inc. (US)
•QIAGEN (Netherlands)
•Siemens Healthineers AG (Germany)
•Becton, Dickinson and Company (US)
•DiaSorin S.p.A (Italy)
•Grifols S.A. (Spain)
•Sysmex Corporation (Japan)
•Seegene Inc. (South Korea)
•Ortho Clinical Diagnostics (US)
•Genetic Signatures (Australia)
•Meridian Bioscience (US)
•OraSure Technologies (US)
•Trinity Biotech Plc. (Ireland)
•Chembio Diagnostic Systems (US)
•Co-Diagnostics (US)
•ELITechGroup (France)
•Epitope Diagnostics (US)
•Trivitron Healthcare (India)
•Meril Life Sciences Pvt. Ltd. (India)
•InBios International (US)
•Uniogen Oy (Finland)
•Vela Diagnostics (Singapore)

Research Coverage:
This report provides a detailed picture of the global infectious disease diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
Table of Contents

1INTRODUCTION32
1.1STUDY OBJECTIVES32
1.2MARKET DEFINITION32
1.2.1INCLUSIONS AND EXCLUSIONS33
1.3MARKETS SCOPE33
1.3.1MARKETS COVERED33
FIGURE 1INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION33
FIGURE 2MARKETS COVERED - BY REGION34
1.3.2INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED34
FIGURE 3YEARS CONSIDERED34
1.4CURRENCY35
1.5LIMITATIONS35
1.6STAKEHOLDERS35
1.7SUMMARY OF CHANGES36
2RESEARCH METHODOLOGY37
2.1RESEARCH DATA37
2.2RESEARCH APPROACH37
FIGURE 4INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY37
2.2.1SECONDARY DATA38
2.2.1.1Key data from secondary sources38
2.2.1.2Secondary research activities39
2.2.2PRIMARY DATA39
2.2.2.1Primary sources40
2.2.2.2Key data from primary sources41
2.2.2.3Key industry insights42
2.2.2.4Breakdown of primary interviews42
FIGURE 5BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS42
FIGURE 6BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION43
2.3MARKET SIZE ESTIMATION43
2.3.1BOTTOM-UP APPROACH44
2.3.1.1Approach 1: Company revenue estimation approach44
FIGURE 7BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH44
2.3.1.2Approach 2: Presentations of companies and primary interviews44
2.3.1.3Growth forecast44
2.3.1.4CAGR projections45
FIGURE 8CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS45
2.3.2TOP-DOWN APPROACH45
FIGURE 9INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH45
2.4MARKET BREAKDOWN AND DATA TRIANGULATION47
FIGURE 10DATA TRIANGULATION METHODOLOGY47
2.5MARKET SHARE48
2.6STUDY ASSUMPTIONS48
2.7LIMITATIONS49
2.8GROWTH RATE ASSUMPTIONS49
2.9RISK ASSESSMENT49
2.9.1RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET49
3EXECUTIVE SUMMARY50
FIGURE 11INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)50
FIGURE 12INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION)51
FIGURE 13INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2022 VS. 2027 (USD MILLION)51
FIGURE 14INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)52
FIGURE 15INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION)52
4PREMIUM INSIGHTS54
4.1INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW54
FIGURE 16RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD54
4.2INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION)55
FIGURE 17REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 202255
4.3INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION)55
FIGURE 18IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD55
4.4INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 202756
FIGURE 19DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET56
5MARKET OVERVIEW57
5.1INTRODUCTION57
5.2MARKET DYNAMICS57
FIGURE 20INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES57
5.2.1DRIVERS58
5.2.1.1Global prevalence of infectious diseases58
5.2.1.2Rising focus on R&D and funding in infectious disease diagnostics58
5.2.1.3Growing awareness for early disease diagnosis in developing countries59
5.2.1.4Rising technological advancements in infectious disease diagnostics60
5.2.1.5Shift in focus from centralized laboratories to decentralized
POC testing60
5.2.2RESTRAINTS61
5.2.2.1Unfavorable reimbursement scenario61
5.2.3OPPORTUNITIES61
5.2.3.1Growth opportunities in growing economies61
5.2.4CHALLENGES62
5.2.4.1Changing regulatory landscape62
5.2.4.2Operational barriers62
5.2.5IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET62
5.3PRICING ANALYSIS64
5.3.1INDICATIVE PRICING MODEL ANALYSIS64
TABLE 1INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022)64
5.4PATENT ANALYSIS65
FIGURE 21LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES65
5.4.1LIST OF MAJOR PATENTS66
5.5VALUE CHAIN ANALYSIS66
FIGURE 22VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES67
5.6SUPPLY CHAIN ANALYSIS67
FIGURE 23INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS68
5.7ECOSYSTEM MARKET MAP68
FIGURE 24INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP69
5.7.1INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM69
5.8PORTER’S FIVE FORCES ANALYSIS70
TABLE 2INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS70
5.8.1THREAT FROM NEW ENTRANTS70
5.8.2THREAT FROM SUBSTITUTES70
5.8.3BARGAINING POWER OF BUYERS70
5.8.4BARGAINING POWER OF SUPPLIERS70
5.8.5DEGREE OF COMPETITION71
5.9PESTLE ANALYSIS71
5.10REGULATORY LANDSCAPE72
5.10.1REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS72
TABLE 3NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS72
TABLE 4ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS72
TABLE 5LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS73
TABLE 6REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS73
5.10.2NORTH AMERICA73
5.10.2.1US73
5.10.2.2Canada73
5.10.3EUROPE74
TABLE 7EUROPE: CLASSIFICATION OF DEVICES74
5.10.4ASIA PACIFIC74
5.10.4.1China74
5.10.4.2Japan74
5.10.4.3India75
5.10.5LATIN AMERICA75
5.10.5.1Brazil75
5.10.5.2Mexico75
5.10.6MIDDLE EAST76
5.10.7AFRICA76
5.11TRADE ANALYSIS76
5.11.1TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS76
TABLE 8IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)76
TABLE 9EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)77
5.12TECHNOLOGY ANALYSIS77
5.13KEY CONFERENCES & EVENTS IN 2022–202378
TABLE 10INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS78
5.14TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES80
5.14.1REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-1980
5.14.2REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET80
5.15KEY STAKEHOLDERS & BUYING CRITERIA81
5.15.1KEY STAKEHOLDERS IN BUYING PROCESS81
FIGURE 25INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS81
TABLE 11INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)81
5.15.2BUYING CRITERIA82
FIGURE 26KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS82
TABLE 12KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS82
5.16CASE STUDY83
FIGURE 27CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING
BEHAVIOUR IN INDIA83
6INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE84
6.1INTRODUCTION85
TABLE 13INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)85
TABLE 14PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)85
6.2REAGENTS, KITS, AND CONSUMABLES86
6.2.1RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH86
TABLE 15INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)87
6.3INSTRUMENTS87
6.3.1INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND87
TABLE 16KEY INSTRUMENTS AVAILABLE IN MARKET88
TABLE 17INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)89
6.4SOFTWARE & SERVICES89
6.4.1GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE
SEGMENT GROWTH89
TABLE 18INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET,
BY REGION, 2020–2027 (USD MILLION)90
7INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING91
7.1INTRODUCTION92
TABLE 19INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,
2020–2027 (USD MILLION)92
7.2LABORATORY TESTING92
7.2.1RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE
MARKET GROWTH92
TABLE 20INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING,
BY REGION, 2020–2027 (USD MILLION)93
7.3POC TESTING93
7.3.1INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH93
TABLE 21INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020–2027 (USD MILLION)94
7.3.2GLOBAL POC TESTING MARKET, BY END USER94
TABLE 22GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)94
TABLE 23GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)95
TABLE 24GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2020–2027 (USD MILLION)95
TABLE 25US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)95

7.3.3POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT96
TABLE 26US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION)96
8INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY97
8.1INTRODUCTION98
8.2PRIMARY NOTES98
8.2.1KEY INDUSTRY INSIGHTS98
TABLE 27INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)98
8.3IMMUNODIAGNOSTICS99
8.3.1RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH99
TABLE 28INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS,
BY REGION, 2020–2027 (USD MILLION)99
8.3.2IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE100
TABLE 29US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)100
8.4PCR100
8.4.1EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH100
TABLE 30INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)101
8.5CLINICAL MICROBIOLOGY101
8.5.1GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE
MARKET GROWTH101
TABLE 31INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020–2027 (USD MILLION)102
8.6INAAT102
8.6.1COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH102
TABLE 32MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)103
8.7DNA SEQUENCING & NGS103
8.7.1INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH103
TABLE 33INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)104
8.8DNA MICROARRAY104
8.8.1GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH104
TABLE 34INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY,
BY REGION, 2020–2027 (USD MILLION)105
8.9OTHER TECHNOLOGIES105
TABLE 35INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2020–2027 (USD MILLION)105

9INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE106
9.1INTRODUCTION107
TABLE 36INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)107
9.2COVID-19107
9.2.1OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE107
TABLE 37INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (USD MILLION)108
TABLE 38INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (MILLION TESTS)108
TABLE 39INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020–2027 (USD MILLION)109
9.3HEPATITIS109
9.3.1INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH109
TABLE 40INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (USD MILLION)110
TABLE 41INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (MILLION TESTS)110
TABLE 42INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020–2027 (USD MILLION)110
9.4HIV111
9.4.1HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH111
TABLE 43INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION,
2020–2027 (USD MILLION)111
TABLE 44INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION,
2020–2027 (MILLION TESTS)112
9.5HOSPITAL-ACQUIRED INFECTIONS112
9.5.1RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH112
TABLE 45INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION,
2020–2027 (USD MILLION)113
TABLE 46INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION,
2020–2027 (MILLION TESTS)113
9.6MOSQUITO-BORNE DISEASES113
9.6.1INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH113
TABLE 47MAJOR PRODUCTS: DENGUE TESTING114
TABLE 48INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020–2027 (USD MILLION)115
9.7HPV115
9.7.1TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH115
TABLE 49INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION,
2020–2027 (USD MILLION)116
TABLE 50INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION,
2020–2027 (MILLION TESTS)116

9.8CHLAMYDIA TRACHOMATIS116
9.8.1GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH116
TABLE 51INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION,
2020–2027 (USD MILLION)117
TABLE 52INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION,
2020–2027 (MILLION TESTS)117
9.9NEISSERIA GONORRHEA118
9.9.1RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH118
TABLE 53INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION,
2020–2027 (USD MILLION)118
9.10TUBERCULOSIS118
9.10.1INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH118
TABLE 54INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY REGION, 2020–2027 (USD MILLION)119
TABLE 55INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY REGION, 2020–2027 (MILLION TESTS)119
TABLE 56INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY METHOD, 2020–2027 (USD MILLION)120
9.11INFLUENZA120
9.11.1RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH120
TABLE 57INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (USD MILLION)121
TABLE 58INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (MILLION TESTS)121
TABLE 59INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020–2027 (USD MILLION)121
9.12SYPHILIS122
9.12.1GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH122
TABLE 60INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020–2027 (USD MILLION)122
9.13OTHER INFECTIOUS DISEASES122
TABLE 61INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)123
10INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER124
10.1INTRODUCTION125
TABLE 62INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)125
10.2DIAGNOSTIC LABORATORIES125
10.2.1INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE125
TABLE 63INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)126
10.3HOSPITALS & CLINICS126
10.3.1INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH126
TABLE 64INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2020–2027 (USD MILLION)127
10.4ACADEMIC RESEARCH INSTITUTES127
10.4.1FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH127
TABLE 65INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)128
10.5OTHER END USERS128
TABLE 66INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY REGION, 2020–2027 (USD MILLION)129
11INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION130
11.1INTRODUCTION131
TABLE 67INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2020–2027 (USD MILLION)131
11.2NORTH AMERICA131
FIGURE 28NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT132
TABLE 68NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION)133
TABLE 69NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)133
TABLE 70NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)133
TABLE 71NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)134
TABLE 72NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION)134
11.2.1US135
11.2.1.1Increasing prevalence of infectious diseases to drive market growth135
TABLE 73US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)135
TABLE 74US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)136
TABLE 75US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)136
TABLE 76US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)137
11.2.2CANADA137
11.2.2.1Focus on affordable tests to drive market growth137
TABLE 77CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)137
TABLE 78CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)138
TABLE 79CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)138
TABLE 80CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)139
11.3EUROPE139
TABLE 81EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION)140
TABLE 82EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)140
TABLE 83EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)141
TABLE 84EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)141
TABLE 85EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)142
11.3.1GERMANY142
11.3.1.1Increasing healthcare expenditure to drive market growth142
TABLE 86GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)143
TABLE 87GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)143
TABLE 88GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)144
TABLE 89GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)144
11.3.2UK145
11.3.2.1Growing number of accredited diagnostic laboratories to propel market growth145
TABLE 90UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)145
TABLE 91UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)146
TABLE 92UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION)146
TABLE 93UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)147
11.3.3FRANCE147
11.3.3.1Rising R&D expenditure and increasing demand for early diagnosis to drive market growth147
TABLE 94FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)147
TABLE 95FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)148
TABLE 96FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)148
TABLE 97FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)149

11.3.4ITALY149
11.3.4.1Adoption of advanced diagnostic technologies to drive market growth149
TABLE 98ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)150
TABLE 99ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)150
TABLE 100ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)151
TABLE 101ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)151
11.3.5SPAIN152
11.3.5.1Rising geriatric population to drive market growth152
TABLE 102SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)152
TABLE 103SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)153
TABLE 104SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)153
TABLE 105SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)154
11.3.6REST OF EUROPE154
TABLE 106REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)154
TABLE 107REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)155
TABLE 108REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)155
TABLE 109REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION)156
11.4ASIA PACIFIC156
FIGURE 29ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT157
TABLE 110ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)157
TABLE 111ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)158
TABLE 112ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)158
TABLE 113ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)159
TABLE 114ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)159
11.4.1CHINA160
11.4.1.1Growing public access to modern healthcare to drive market growth160
TABLE 115CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)160
TABLE 116CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)161
TABLE 117CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)161
TABLE 118CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)162
11.4.2JAPAN162
11.4.2.1Universal healthcare reimbursement policy to drive market growth162
TABLE 119JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)163
TABLE 120JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)163
TABLE 121JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)164
TABLE 122JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)164
11.4.3INDIA165
11.4.3.1Increasing private & public investments in healthcare system to drive market growth165
TABLE 123INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)165
TABLE 124INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)166
TABLE 125INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)166
TABLE 126INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION)167
11.4.4REST OF ASIA PACIFIC167
TABLE 127REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)167
TABLE 128REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)168
TABLE 129REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)168
TABLE 130REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION)169
11.5LATIN AMERICA169
11.5.1RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS169
TABLE 131LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)170
TABLE 132LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)170
TABLE 133LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)171
TABLE 134LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)171

11.6MIDDLE EAST & AFRICA172
11.6.1RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH172
TABLE 135MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)172
TABLE 136MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION)173
TABLE 137MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION)173
TABLE 138MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION)174
12COMPETITIVE LANDSCAPE175
12.1OVERVIEW175
12.2KEY PLAYER STRATEGIES/RIGHT TO WIN175
12.2.1OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS175
TABLE 139OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES175
12.3REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS177
FIGURE 30REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET177
12.4MARKET SHARE ANALYSIS178
12.4.1INFECTIOUS DISEASE DIAGNOSTICS MARKET178
FIGURE 31INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)178
TABLE 140INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION178
12.5COMPANY EVALUATION QUADRANT179
12.5.1LIST OF EVALUATED VENDORS179
12.5.2STARS179
12.5.3EMERGING LEADERS179
12.5.4PERVASIVE PLAYERS180
12.5.5PARTICIPANTS180
FIGURE 32INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021180
12.6COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021)181
12.6.1PROGRESSIVE COMPANIES181
12.6.2STARTING BLOCKS181
12.6.3RESPONSIVE COMPANIES181
12.6.4DYNAMIC COMPANIES181
FIGURE 33INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021182
12.7COMPETITIVE BENCHMARKING183
12.7.1PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS183
FIGURE 34PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET183
TABLE 141INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS183
TABLE 142COMPANY PRODUCT & SERVICE FOOTPRINT184
TABLE 143COMPANY REGIONAL FOOTPRINT184
TABLE 144INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES185
12.8COMPETITIVE SCENARIO185
12.8.1PRODUCT LAUNCHES185
TABLE 145KEY PRODUCT LAUNCHES & REGULATORY APPROVALS185
12.8.2DEALS186
TABLE 146KEY DEALS186
13COMPANY PROFILES187
(Business overview, Products offered, Recent Developments, MNM view)*
13.1KEY PLAYERS187
13.1.1ABBOTT LABORATORIES187
TABLE 147ABBOTT LABORATORIES: BUSINESS OVERVIEW187
FIGURE 35ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)188
TABLE 148PRODUCT LAUNCHES & APPROVALS191
13.1.2F. HOFFMANN-LA ROCHE LTD.193
TABLE 149F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW193
FIGURE 36F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)194
13.1.3THERMO FISHER SCIENTIFIC INC.199
TABLE 150THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW199
FIGURE 37THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)200
13.1.4SIEMENS HEALTHINEERS AG204
TABLE 151SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW204
FIGURE 38SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)205
13.1.5BIOMÉRIEUX SA209
TABLE 152BIOMÉRIEUX SA: BUSINESS OVERVIEW209
FIGURE 39BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)210
13.1.6DANAHER CORPORATION215
TABLE 153DANAHER CORPORATION: BUSINESS OVERVIEW215
FIGURE 40DANAHER CORPORATION: COMPANY SNAPSHOT (2021)216
13.1.7HOLOGIC, INC.220
TABLE 154HOLOGIC, INC.: BUSINESS OVERVIEW220
FIGURE 41HOLOGIC, INC.: COMPANY SNAPSHOT (2021)221
13.1.8BECTON, DICKINSON AND COMPANY224
TABLE 155BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW224
FIGURE 42BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)225
13.1.9PERKINELMER, INC.230
TABLE 156PERKINELMER, INC.: BUSINESS OVERVIEW230
FIGURE 43PERKINELMER, INC.: COMPANY SNAPSHOT (2021)231
13.1.10SEEGENE, INC.235
TABLE 157SEEGENE, INC.: BUSINESS OVERVIEW235
FIGURE 44SEEGENE, INC.: COMPANY SNAPSHOT (2021)236
13.1.11QUIDEL CORPORATION240
TABLE 158QUIDEL CORPORATION: BUSINESS OVERVIEW240
FIGURE 45QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)240
13.1.12QIAGEN N.V.245
TABLE 159QIAGEN N.V.: BUSINESS OVERVIEW245
FIGURE 46QIAGEN N.V.: COMPANY SNAPSHOT (2021)246
13.1.13DIASORIN S.P.A250
TABLE 160DIASORIN S.P.A: BUSINESS OVERVIEW250
FIGURE 47DIASORIN S.P.A: COMPANY SNAPSHOT (2021)251
13.1.14BIO-RAD LABORATORIES, INC.258
TABLE 161BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW258
FIGURE 48BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)259
13.1.15GRIFOLS S.A.263
TABLE 162GRIFOLS S.A.: BUSINESS OVERVIEW263
FIGURE 49GRIFOLS S.A.: COMPANY SNAPSHOT (2021)264
13.1.16ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC266
TABLE 163ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW266
FIGURE 50ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY
SNAPSHOT (2021)267
13.1.17SYSMEX CORPORATION270
TABLE 164SYSMEX CORPORATION: BUSINESS OVERVIEW270
FIGURE 51SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)270
13.2OTHER PLAYERS272
13.2.1MERIDIAN BIOSCIENCE272
13.2.2ORASURE TECHNOLOGIES274
13.2.3CO-DIAGNOSTICS275
13.2.4CHEMBIO DIAGNOSTIC SYSTEMS276
13.2.5TRINITY BIOTECH PLC277
13.2.6GENETIC SIGNATURES LTD.278
13.2.7EPITOPE DIAGNOSTICS279
13.2.8TRIVITRON HEALTHCARE280
13.2.9ELITECHGROUP281
13.2.10MERIL LIFESCIENCES PVT. LTD.283
13.2.11INBIOS INTERNATIONAL283
13.2.12UNIOGEN OY285
13.2.13VELA DIAGNOSTICS285
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14APPENDIX287
14.1DISCUSSION GUIDE287
14.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL291
14.3AVAILABLE CUSTOMIZATIONS293
14.4RELATED REPORTS293
14.5AUTHOR DETAILS294

Report Title: Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW